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Abstract
Objectives. Intravenous infusion of Intralipid is an adjunct therapy
in assisted reproduction treatment (ART) when immune-associated
infertility is suspected. Here, we evaluated the effect of Intralipid
infusion on regulatory T cells (Treg cells), effector T cells and
plasma cytokines in peripheral blood of women undertaking IVF.
Methods. This prospective, observational pilot study assessed
Intralipid infusion in 14 women exhibiting recurrent implantation
failure, a clinical sign of immune-associated infertility. Peripheral
blood was collected immediately prior to and 7 days after
intravenous administration of Intralipid. Plasma cytokines were
measured by Luminex, and T-cell subsets were analysed by flow
cytometry. Results. A small increase in conventional CD8+ T cells
occurred after Intralipid infusion, but no change was seen in CD4+
Treg cells, or na€ıve, memory or effector memory T cells.
Proliferation marker Ki67, transcription factors Tbet and RORct,
and markers of suppressive capacity CTLA4 and HLA-DR were
unchanged. Dimensionality-reduction analysis using the tSNE
algorithm confirmed no phenotype shift within Treg cells or other
T cells. Intralipid infusion increased plasma CCL2, CCL3, CXCL8,
GM-CSF, G-CSF, IL-6, IL-21, TNF and VEGF. Conclusion. Intralipid
infusion elicited elevated pro-inflammatory cytokines, and a minor
increase in CD8+ T cells, but no change in pro-tolerogenic Treg
cells. Notwithstanding the limitation of no placebo control, the
results do not support Intralipid as a candidate intervention to
attenuate the Treg cell response in women undergoing ART.
Future placebo-controlled studies are needed to confirm the
potential efficacy and clinical significance of Intralipid in
attenuating cytokine induction and circulating CD8+ T cells.
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INTRODUCTION
Recurrent implantation failure occurs when
overtly healthy embryos fail to implant over the
course of repeated IVF cycles. This condition
affects at least 10% of infertile women seeking
in vitro fertilisation (IVF) treatment,1 and is
thought to reflect failure of the uterine
endometrial lining to attain a sufficiently
receptive state. Several factors likely contribute to
impaired endometrial receptivity, but the uterine
immune response and failure to acquire adequate
immune tolerance are viewed as a likely cause in
many women.2 For embryo implantation and
formation of a robust placenta to support optimal
fetal growth and development, a state of
adaptive immune tolerance mediated by
tolerogenic CD4+ regulatory T cells (Treg cells) is
required.3 Tregs are well known for their capacity
to limit excessive inflammation and recalibrate
tissue homeostasis after insult or injury, as well as
to suppress effector T-cell reactions to self or non-
self antigens.4,5 In fetal tolerance, CD4+ Treg cells
are required to suppress inflammation, prevent
effector T-cell generation and support uterine
vascular adaptations that underpin placental
development.4–6
During early pregnancy, T cells comprise
10–20% of uterine immune cells.7 Many of these
are CD8+ T cells, including regulatory subsets.8,9
Amongst the CD4+ T cells, about 10–30% express
the Treg transcription factor FOXP3, a substantial
enrichment compared with peripheral blood.10–12
The majority of T cells in the human decidua have
a memory phenotype (CD45RA or CD45RO+).9,13
Decidual Th1 cell frequencies are moderately
elevated, while Th17 and Th2 cells are generally
not enriched, reflecting a mild inflammatory
environment modulated by Treg cells.11,14 Indeed,
sufficient Treg cells must be present in the
endometrium to suppress inflammation and allow
successful embryo implantation to occur.15
As well as T cells, there are abundant
populations of innate immune cells in the
decidua, particularly macrophages,16 dendritic
cells17 and a unique population of NK cells with a
CD56hiCD57lo phenotype (uterine NK cells or uNK
cells).18 Treg cells may be important regulators of
uNK phenotype and function at implantation,19
since Treg cells control IL-15 release from DCs20
and suppress uNK cytolytic activity.21 The
abundance, phenotype and function of these
immune cell networks are modulated by a
complex array of pro-inflammatory and immune-
modulatory cytokines and chemokines in the
uterine endometrium.22–24 Shifts in the
endometrial cytokine balance can impact the
maternal immune response and modify the
events of placental development, to either
promote or compromise progression of a viable
pregnancy.3
Treg cell-mediated tolerance arises in the pre-
implantation phase of early pregnancy and
depends on interactions between maternal,
paternal and conceptus-derived signals at the
mucosal surface of the uterine endometrium.3
Uterine Treg cells are recruited from precursors
circulating in the peripheral blood, after
proliferation and expansion in lymph nodes
draining the uterus.3 Studies in cycling women
show that peripheral blood and uterine Tregs
fluctuate over the course of the menstrual cycle in
response to regulation by oestrogen and
progesterone, increasing in the peri-ovulatory and
early luteal phase in readiness for embryo
implantation.3,25 Several studies report that
recurrent implantation failure is associated with
insufficient Treg cells in the uterine mucosa or
decidual lining.26–28 This is reflected in fewer
numbers of these cells in the peripheral blood,27
and IVF success correlates with circulating levels of
CD4+CD25+FOXP3+ cells,29,30 suggesting a systemic
defect. Associations between reduced fertility and
fewer Tregs in asthma, allergy and autoimmune
disease support systemic Treg cell dysfunction
being an underlying cause.31 This has raised the
imperative to develop and evaluate interventions
that boost Treg cells in women experiencing
recurrent implantation failure with an immune
aetiology.2
Intralipid is a sterile lipid emulsion of
polyunsaturated fatty acids derived from soya
bean oil and egg yolk phospholipids used for
parenteral nutritional support. Lipid emulsion
formulations are demonstrated to have a variety
of immune-modulatory, anti-inflammatory and
antioxidative properties, depending on the
specific composition and particularly the balance
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of omega-3 and omega-6 polyunsaturated fatty
acid (PUFA) content.32 Many reproductive
medicine clinics offer Intralipid as a so-called ‘add-
on’ therapy, often at considerable cost to
patients.33,34 However, routine use of Intralipid in
IVF is not supported by robust evidence of safety
and efficacy.35 Several small clinical studies
suggest that Intralipid therapy may exert
therapeutic benefit for women experiencing
repeated implantation failure,36–40 but this is not
a consistent finding.35,41,42 A recent meta-analysis
concluded a modest positive benefit for women
with implantation failure, but because of the
small sample size, it is cautioned that more
evidence is needed before routine application can
be recommended.43 Although this potential
benefit is presumed to occur through effects on
immune adaptation to pregnancy, the biological
rationale and mechanism of action in
reproductive-aged women is not clear,43 and
whether Intralipid might affect Treg cell-mediated
tolerance is unknown.
While it has been claimed that Intralipid may
attenuate aberrant populations of uNK cells, this
is based on a single report that Intralipid reduces
NK cell cytotoxic activity in vitro,44 and only one
study has reported that Intralipid may decrease
NK cell frequency in peripheral blood.39
Furthermore, although increased NK cell activity is
regularly linked with pregnancy failure, the
significance of this is disputed.45 Based on studies
of the effects of lipid emulsions in other clinical
settings, there is a biological rationale to suggest
that Intralipid might alter the abundance or
phenotype of T cells important for uterine
receptivity.32,46,47 However, no studies to date
have examined the effects of Intralipid on uterine
or peripheral blood T cells in reproductive-aged
women, despite their importance in maternal
immune tolerance of pregnancy.
To explore the possibility that T cells might be
responsive to Intralipid infusion in women with
recurrent implantation failure, we examined T
cells in peripheral blood taken from women
before and after Intralipid infusion in women
undertaking IVF. Specifically, we utilised multi-
parameter analysis to allow detailed
characterisation of the effects of intravenous
Intralipid on beneficial anti-inflammatory Treg
cells, and potentially detrimental T effector
immunity, or to compare T-cell populations and
cytokine and chemokine abundance before and
after Intralipid treatment.
RESULTS
Participant characteristics, clinical outcome,
CRP and white blood cell parameters
The study participants included 14 women, with a
mean  SD (range) age of 35.8  4.5 (27–43)
years, BMI of 25.7  7.4 (18.4–41.4), and total
number of embryos transferred in prior ART cycles
of 4.6  2.0 (2–8) (Table 1). IVF treatment
outcomes in the study cycle showed embryo
implantation occurred in 8 women as indicated by
a positive hCG test, leading to live birth in 5 of
14, early miscarriage (termed ‘early biochemical
miscarriage’, EBM) in 2 women and 1 ectopic
pregnancy. The remaining 6 women experienced
implantation failure (Table 1). Intralipid did not
alter the relative abundance of total white blood
cells, neutrophils, lymphocytes, monocytes,
eosinophils or basophils in peripheral blood, as
indicated by comparison of the pre-Intralipid and
post-Intralipid samples (Supplementary table 2). C-
reactive protein (CRP), a biomarker of systemic
inflammation, was also not changed after
Intralipid infusion (median (range) = 2.3 (0–20)
before and 5.1 (0–47) after Intralipid).
Increased CD8+ Tconv cells but not CD4+ T
cells or Tregs after Intralipid by 2D flow
cytometry
To investigate the effect of Intralipid treatment
on peripheral blood T cells, cryopreserved
peripheral blood mononuclear cells (PBMCs) from
pre- and post-Intralipid blood samples were
thawed, stained with antibodies against a panel
of T-cell markers and analysed by flow cytometry.
Initially, flow cytometric data analysis utilised a
conventional manual gating (2D) approach. A
small reduction in the proportion of CD4+ T cells
amongst total CD3+ T cells was present after
Intralipid treatment, from a median of 67.2% of
CD3+ T cells at baseline to 65.0% after Intralipid
(P = 0.027), although neither conventional
CD4+FOXP3 T cells (Tconv) nor
CD4+CD25+CD127loFOXP3+ Treg cells were
significantly different (Figure 1a–d). Conversely,
total CD8+ T cells amongst CD3+ T cells were
proportionally increased after Intralipid, because
of a small increase in CD8+FOXP3 Tconv cells
from a median of 27.2% to 29.3% post-Intralipid
(P = 0.026). CD8+CD25+CD127loFOXP3+ Treg cells
comprised only a small proportion of T cells
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(0.06%) and were unchanged by Intralipid
treatment. Notably, analysis of CD4+ FOXP3+ and
CD8+FOXP3+ T cells independently of CD25 and
CD127 expression yielded a similar result of no
effect of Intralipid treatment (data not shown).
The phenotypes of T cells are unaffected by
Intralipid treatment
CD4+ Tconv cells were mostly na€ıve (65.6%) and
central memory T (TCM) cells (20.6%), and there
was no change in their frequency or in effector
memory T cells (TEM) or T effector memory re-
expressing CD45RA (TEMRA) cells post-Intralipid
treatment (Figure 1e). Likewise, the proportions
of effector and memory subsets of CD8+ Tconv
cells were also unchanged by Intralipid treatment
and were mostly of a na€ıve (50.9%) or TEMRA
phenotype (41.4%) (Figure 1f). The effector and
memory subsets of Tregs were also analysed and
found not to be changed by Intralipid treatment
(Figure 1g). Most Tregs exhibited a na€ıve
phenotype (46.7%) although some TCM (17.3%),
TEM (24.5%) and TEMRA (7.2%) were also present.
There was no difference in the frequency of
CD4+ Tconv, CD8+ Tconv or Tregs that expressed
Tbet or RORct, indicating no bias towards Th1 or
Th17 immunity (Supplementary figure 1a). No
change was found in the expression of the
exhaustion marker CTLA4 by CD4+ and CD8+ Tconv
cells, as measured by both percentage of CTLA4+
cells and mean fluorescence index (MFI)
(Figure 2a, b). Treg expression of CTLA4, which is
associated with immunosuppressive function, was
also similar in pre- and post-Intralipid samples.
HLA-DR is another molecule expressed by some
Tregs, and its increased expression level is
associated with suppressive phenotype.48 Like
CTLA4, no difference in Treg expression of HLA-
DR was detected after Intralipid treatment
(Figure 2e, f).
Few Tconv cells were proliferating as measured
by Ki67 expression, representing only 0.30% and
0.42% of CD4+ and CD8+ Tconv, respectively
(Figure 2c, d). Comparatively, a higher proportion
of CD4+ Tregs (2.05%) were proliferating
(Figure 2c, d), but no differences in proliferation
of any of these T-cell subsets were detected after
Intralipid treatment.
tSNE clustering analysis showed no change
in T-cell subsets after Intralipid
Additionally, flow cytometric data were analysed
using an unbiased, dimensionality-reducing and
clustering algorithm to investigate differences
between T cells in pre- versus post-Intralipid blood
samples. A sample of 3500 live CD3+ T cells was
randomly selected from each pre- and post-
Intralipid PBMC sample and the clustering
algorithm Xshift employed to define T-cell
subpopulations in an unbiased manner. The tSNE
Table 1. Study participant characteristics
Participant Age BMI Total embryos transferreda Embryo implantation Pregnancy outcome
A 40 36.2 6 Yes EBMa
B 37 25.1 3 Yes Live birth
C 37 19.6 5 No No
D 27 18.4 2 Yes Ectopic
E 38 N/A 6 No No
F 43 32.1 4 No No
G 37 24.6 7 Yes Live birth
H 28 19.0 3 Yes Live birth
I 34 29.9 3 Yes Live birth
J 35 18.5 2 No No
K 33 41.4 4 Yes EBM
L 35 19.6 4 No No
M 34 26.5 7 Yes Live birth
N 43 22.9 8 No No
all 35.8  4.7 25.7  7.4 4.6  2.0 LBR = 35.7%
BMI, body mass index; EBM, early biochemical miscarriage; Ectopic, ectopic pregnancy; LBR, live birth rate.
Summary data are mean  standard deviation.
aTotal embryos transferred = sum of prior ART cycles.
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Figure 1. T-cell populations in peripheral blood before and after Intralipid treatment. Peripheral blood samples obtained before and after
Intralipid treatment were analysed by flow cytometry (N = 28 paired samples from N = 14 women). Differences in T-cell parameters between pre-
and post-Intralipid samples were evaluated by the Wilcoxon matched-pairs signed rank test. (a) Representative flow cytometry showing the
gating of total CD4+ and CD8+ T cells (top row) and their conventional (Tconv) and regulatory (Treg) subpopulations (second and third rows) pre-
and post-Intralipid treatment. (b–d) Proportion of total CD4+ and CD8+ T cells (b), CD4+ Tconv and CD8+ Tconv (c), and CD4+ Treg and CD8+
Tregs (d) in peripheral blood pre- and post-Intralipid treatment. (e–g) Effector and memory T-cell subsets in CD4+ Tconv cells (blue; e), CD8+
Tconv cells (green; f) and CD4+ Tregs (orange; g). TCM = central memory T cells; TEM = effector memory T cells; TEMRA = T effector memory cells
expressing CD45RA. *P < 0.05.
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Figure 2. Expression of CTLA4, Ki67 and HLA-DR by T-cell populations before and after Intralipid treatment. Peripheral blood samples obtained
before and after Intralipid treatment were analysed by flow cytometry (N = 28 paired samples from N = 14 women). Differences in T-cell
parameters between pre- and post-Intralipid samples were evaluated by the Wilcoxon matched-pairs signed rank test. (a) Representative flow
cytometry and graphs (b) of proportion of CTLA4-expressing conventional CD4+ T cells, conventional CD8+ T cells and CD4+ Tregs. (c)
Representative flow cytometry and proportions (d) of proliferating T cells (Ki67+). (e) Representative flow cytometry and proportions (f) of HLA-
DR expression by CD4+ Tregs.
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algorithm was applied to depict the 20 cell
clusters that were identified (Figure 3a). The
expression of each of the markers by the CD3+ T
cells was assessed, and CD4+ and CD8+ T cells were
clustered into two main areas each (Figure 3b). A
heatmap was generated detailing the expression
level of each cell marker by the different T-cell
clusters (Figure 3c). From this heatmap, CD4+ and
CD8+ T cells and Tregs were manually annotated.
PBMCs isolated from women following Intralipid
treatment showed a similar T-cell composition to
baseline PBMCs (Figure 3d, e), and there was no
difference in the Xshift-defined T-cell populations
between the pre- and post-Intralipid samples as
determined by the Wilcoxon matched-pairs signed
rank tests (Supplementary table 3). Thus, unbiased
cell clustering analysis of the flow cytometric data
revealed no changes to T cells in the blood of
women undergoing IVF following Intralipid
treatment.
Increased cytokines and chemokines in post-
Intralipid plasma
Cytokines and chemokines in peripheral blood
plasma are an additional measure of systemic
immune status. Luminex microbead assay was
used to measure the concentrations in plasma of
an array of pro- and anti-inflammatory cytokines
and chemokines with established roles in the
innate and adaptive immune response. Intralipid
infusion was associated with increased plasma
CCL2, CCL3, GM-CSF, G-CSF, IL-6, IL-21 and TNF
(Figure 4a, b, e, g, h, m, q, r and Supplementary
table 4). Vascular endothelial growth factor
(VEGF), which has anti-inflammatory and pro-
angiogenic properties, was also increased
(Figure 4s). Other cytokines and chemokines
including IL-1-receptor alpha (IL-1Ra), IL-2, IL-4, IL-
10, IL-12p70, IL-15, CCL5, CXCL1 and CXCL10 were
unchanged (Figure 4). When effects of Intralipid
were analysed according to implantation success,
significant increases in CCL3, GM-CSF, IL-6, IL-10,
IL-15, IL-21 and VEGF were seen in the post-
Intralipid versus pre-Intralipid plasma samples in
the subset of women where embryo implantation
occurred, but not in women where embryo
implantation did not occur (Table 2,
Supplementary figure 2). However, there was no
association between implantation success or later
live birth and the levels of plasma cytokines
prior to or after Intralipid treatment, or the
degree of cytokine increase between the
pre-Intralipid and post-Intralipid time points
(Table 2, Supplementary figure 2).
DISCUSSION
This study provides the first detailed analysis of
the effects of Intralipid on circulating T cells in
women undergoing assisted reproduction
treatment. In broad terms, we found no increase
in Treg cells, no substantial shift in the balance of
CD4+ or CD8+ regulatory to conventional T cells,
and no indication of altered phenotype in Treg
cells or other T-cell subsets, which were
attributable to Intralipid treatment. In contrast,
Intralipid infusion was associated with changes in
peripheral blood plasma cytokines, notably
elevated CCL2, CCL3, GM-CSF, G-CSF, IL-6, IL-21
and TNF, compared with baseline concentrations.
This could reflect an effect of Intralipid on
circulating immune cells, but, given the pattern of
cytokines seen, is unlikely to be because of T-cell
activation, and is more likely associated with
innate immune cells or non-leucocyte sources. The
data therefore do not support an impact of
Intralipid on Treg cells or other elements of the
adaptive immune response that would be
sufficient to influence embryo implantation or the
likelihood of successful pregnancy.
An important consideration in the
interpretation of the data is the lack of a no-
Intralipid or saline infusion control to compare
the results from Intralipid-treated women. Thus,
we are unable to conclusively attribute the minor
changes in CD8+ T cells or shift in plasma
cytokines to Intralipid, since other factors might
also contribute. As well as endogenous cycle-
related changes in ovarian steroid hormones, all
women were administered exogenous
progesterone according to standard clinical IVF
protocols.49 No other drugs were administered.
While elevated progesterone of endogenous or
exogenous origin can alter peripheral blood
cytokine and immune parameters, many published
studies show that the impact is to reduce pro-
inflammatory cytokines and effector T cells, in line
with the anti-inflammatory effect of this
hormone.50,51 These considerations support the
prospect that the observed immune changes are
because of Intralipid, but further studies are
required to prove this.
While CD4+ T cells were unchanged, a small 8%
increase in median relative proportion of CD8+ T
cells was seen after Intralipid treatment, due
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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Figure 3. Effect of Intralipid treatment on CD3+ T cells in peripheral blood as assessed by t-distributed stochastic neighbour embedding (tSNE).
Peripheral blood samples obtained before and after Intralipid treatment were analysed by flow cytometry (N = 28 paired samples from N = 14
women). A downsample of 3500 CD3+ T cells per sample was concatenated and clustered using Xshift and tSNE algorithms. (a) 2D tSNE
representation of cell clustering. Each colour represents a different T-cell cluster defined by the Xshift algorithm. (b) Expression of each marker
mapped to the tSNE plot. Cells were manually gated for positive expression of each marker, then mapped to the tSNE plot. (c) Heatmap of
expression of each marker by the Xshift-defined cell clusters. The clusters have been grouped into families of CD4+, CD8+ and CD4-CD8- clusters
based on the presence or absence of CD4 or CD8 in the first 2 columns of the heatmap. Blue indicates high expression level of the molecule
relative to other clusters, and white indicates no expression. (d) tSNE plots of CD3+ cells from IVF patients pre- and post-Intralipid treatment. (e)
Proportion of each cell cluster within CD3+ T cells in IVF patients pre- and post-Intralipid treatment.
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Figure 4. Effect of Intralipid treatment on plasma cytokine and chemokine levels. Plasma prepared from peripheral blood obtained before and
after Intralipid treatment was analysed by Milliplex MAP Luminex microbead assay (N = 28 paired samples from N = 14 women) to quantify CCL2
(a), CCL3 (b), CCL5 (c), CXCL1 (d), CXCL8 (e), CXCL10 (f), GM-CSF (g), G-CSF (h), IL-1A (i), IL-1RA (j), IL-2 (k), IL-4 (l), IL-6 (m), IL-10 (n), IL-
12p70 (o), IL-15 (p), IL-21 (q), TNF (r) and VEGF (s). Differences in cytokine and chemokine concentrations between pre- and post-Intralipid
samples were evaluated by the Wilcoxon matched-pairs signed rank test. *P < 0.05, **P < 0.01 and ***P < 0.005.
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mainly to increased CD8+ Tconv as opposed to
CD8+ Treg cells. Whether this elevation in Tconv
cells is beyond normal fluctuations seen over the
course of the menstrual cycle is not certain, but
notably, effector T cells are generally diminished,
not elevated, in the luteal phase.50 Since no
differences were found within the CD8+ Tconv cell
phenotype, the physiological significance in
relation to availability of CD8+ T cells for
recruitment into the uterus is not known.
Compared with circulating CD8+ T cells, decidual
CD8+ T cells display a more differentiated, TEM
phenotype and can recognise fetal antigens,
although they express lower cytolytic molecules
perforin and granzymes.9 Future studies to
evaluate the impact of Intralipid on uterine
immune cells would be required to determine the
relevance of the peripheral blood changes to
potential changes in the uterus. Even if the small
increase in CD8+ Tconv cells was mirrored in the
decidua, any threat posed to reproductive success
would likely be attenuated by uterine Treg cell
populations and high expression of the co-
inhibitory molecule PD-1, which together keep
effector functions of decidual CD8+ Tconv cells in
check.52
Although the current study was not powered to
investigate relationships between IVF treatment
outcome and immune parameters, it was
interesting to consider whether the minor T-cell
changes were evident to a greater or lesser
degree in women who progressed to pregnancy
and/or live birth. In an exploratory analysis, we
compared T-cell data from the 6 women who
experienced implantation failure to data from the
8 women where embryo implantation occurred,
and data from the 5 women where live birth was
achieved. This analysis showed no significant
difference in the post-Intralipid CD8+ T cells, or
other T-cell proportions or phenotypes, and no
indication of a greater change compared with
baseline in these subgroups.
The lack of effect of Intralipid infusion on Treg
cells was in contrast to previous studies showing
that lipid emulsions can alter T-cell parameters
in vitro and in vivo. Different effects of lipid
emulsions are demonstrated, depending on the
lipid composition and notably the balance of
omega-3 and omega-6 PUFA.32,53 As a soya bean-
based emulsion, Intralipid has a 7:1 omega-6:
omega-3 PUFA ratio,54 is generally thought to be
immunosuppressive and is able to inhibit
lymphocyte, macrophage and neutrophil
functions.32,53 In vitro experiments have shown
that T lymphocyte proliferation is suppressed in
the presence of low doses of Intralipid and
related emulsions,46 consistent with a potential
effect on Treg cells. Treg cells are known to have
specific lipid requirements, and FOXP3 induction
can be suppressed when triglyceride uptake and
metabolism is impaired.47 These immune-
regulatory properties are mediated through
impacts on eicosanoid synthesis and direct effects
on cytokine synthesis,55 potentially via regulation
of the peroxisome proliferator-activated receptors
(PPARs), which modulate the expression of genes
involved in the immune and inflammatory
response, for example by antagonising NFjB
signalling.56
Whether or how the induction of CCL2, CCL3,
GM-CSF, G-CSF, IL-6, IL-21 and TNF after Intralipid
infusion might have a bearing on embryo
implantation is not clear. Several previous studies
indicate a local inflammation-like response in the
uterine endometrium is required at embryo
implantation, in order to facilitate maternal
immune adaptation for pregnancy.3,22,23 The
cytokines that were elevated after Intralipid
infusion each has pro-inflammatory and immune-
regulatory properties, and all are expressed in the
endometrium during early pregnancy.22,24,57 This
local inflammatory state is accompanied by
systemic indicators of inflammatory activation, as
evidenced by higher plasma CRP levels in
pregnant than in non-pregnant IVF patients
detectable from 10 days after embryo transfer.58
Elevated CRP associated with implantation success
was not detected in the current study, presumably
because of the earlier sampling time, and the
small number of women evaluated.
In the absence of a no-Intralipid control group,
it is not possible to attribute conclusively the
elevated plasma cytokines to Intralipid treatment.
However, for all cytokines other than TNF, the
cytokine induction after Intralipid was
substantially greater than the expected increase
because of cycle-related fluctuations.59–62
Intralipid is known to exert pro-inflammatory
effects by virtue of its high content of omega-6
PUFAs, which metabolise to 2-series
prostaglandins and thromboxanes, and 4-series
leukotrienes.54 In line with the current data, a
previous study reported that Intralipid infusion
acts to elevate TNF and IL-6 in response to low-
dose endotoxaemia in humans.63 It is possible that
local synthesis in the uterus because of embryo
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implantation contributed to elevated plasma
cytokines after Intralipid, especially given that
increases were more consistently seen in women
with successful implantation. However, this is
unlikely given that the post-Intralipid sample was
recovered so early after implantation commences,
and before extensive trophoblast invasion could
occur. It is possible that differential degrees of
cytokine induction reflect varying levels of
systemic responsiveness to Intralipid stimulation.
Therefore, possible implications for fertility of the
elevated changes in cytokine and chemokine
levels in post-Intralipid plasma samples are
discussed below.
The greatest changes after Intralipid were in IL-
6 and CXCL8, both of which play important roles
in uterine spiral artery remodelling to facilitate
early placental development.64 First-trimester
miscarriage is associated with reduced IL-6 and
CXCL8 production,65 and lower IL-6 transcription
is evident in the uterine endometrium of women
with recurrent miscarriages, compared with fertile
women.66 Intralipid is potentially responsible for
the effect on IL-6, given that no increase in IL-6
usually occurs in the luteal phase.51,67 Continued
elevation in plasma IL-6 and CXCL8 as pregnancy
progresses, indicating excessive inflammatory
activation, is linked to preeclampsia68 and
spontaneous second-trimester abortion.69 The
increase in TNF seen in the post-Intralipid plasma
is unlikely to be caused by Intralipid, since TNF is
usually elevated to a similar degree in the luteal
phase of the menstrual cycle.51,62
CCL2 is thought to promote Treg recruitment to
the endometrium,70 and myeloid-derived
suppressor cells that are increased in early
pregnancy are induced by CCL2 in an autocrine
manner.71 However, a sustained increase in plasma
CCL2 is associated with recurrent spontaneous
abortion (RSA).72 At very high levels, elevated
plasma CCL3 is also linked with RSA.73 IL-21 is
associated with Th1- and Th17-polarised immune
responses, and the 15% increase in median IL-21 in
post-Intralipid blood samples might reflect
elevated production by Th17 cells and NK cells.74
Plasma G-CSF usually declines from the peri-
ovulatory to luteal phase,60 increasing the prospect
that Intralipid modulates this cytokine. GM-CSF acts
to promote blastocyst survival and implantation
competence.75,76 Plasma GM-CSF levels increased in
the first trimester of normal healthy pregnancies,
but not in women with recurrent miscarriage.77
Clinical studies show G-CSF has therapeutic
potential in women with recurrent implantation
failure,78 potentially via inducing tolerogenic
dendritic cells that promote immune tolerance or
improve endometrial thickness.79
Vascular endothelial growth factor promotes
angiogenesis, which is essential for placental
development. VEGF is elevated in the endometrial
tissue of women who later have successful
pregnancy outcome57 and is reduced in women
with recurrent implantation failure.80,81 Serum
VEGF does not fluctuate over the cycle but is
elevated in the mid-luteal phase in women
undertaking IVF, where it correlates with body
mass index and plasma progesterone.59 Similar to
the current result, a previous study in women
showed Intralipid therapy to boost plasma VEGF
and CCL2 levels, although this was outside the
context of IVF and pregnancy.82
Reasonably, it might be expected that if
Intralipid exerts beneficial effects on implantation
success, higher levels of plasma cytokines and/or
greater increases after Intralipid treatment would
be seen in the women where embryo implantation
and/or progression to live birth occurred. There
was no evidence of higher plasma cytokines or a
greater change of cytokines in these subgroups,
just a more consistent difference between the pre-
Intralipid and post-Intralipid time points. However,
it is important to note that the study was not
powered to discriminate effects in these
subgroups, so no firm conclusion on associations
with reproductive success can be drawn.
The relatively small sample size is a limitation of
this study, and we acknowledge that detection of
subtle changes would require more study
participants. Additionally, the possibility of
phenotypic changes in other leucocyte
populations was not evaluated here. Although
the proportions of white blood cell subsets did
not change after Intralipid, effects on function or
phenotype of NK cells, macrophages or other
innate immune cells that benefit pregnancy are
possible. In particular, NK cells are thought to
respond to Intralipid therapy and effects on these
cells may be important in the setting of recurrent
pregnancy loss and repeated implantation
failure.83
CONCLUSION
These data suggest that Intralipid infusion in
women receiving treatment for suspected
immune-associated infertility elicits induction of
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several cytokines linked with systemic immune
activation that have potential to improve
endometrial receptivity and implantation success.
Elevated plasma cytokines were not linked with
alterations to circulating T lymphocytes sufficient
to implicate the adaptive immune response as
being responsive to Intralipid therapy. The data
imply that Intralipid treatment may elicit small
changes in CD8+ Tconv cells but does not affect
CD4+ T cells including Treg cells. If Intralipid
induces immune changes to favor pregnancy
success, then the mechanism may involve other
immune cell types. The changes outlined in this
study warrant confirmation in future studies that
include a no-treatment or sham treatment
control.
METHODS
Ethics approval and study design
Approval for this study was obtained from the human
research ethics committee at the University of South
Australia, application ID36581, and the scientific advisory
committee at Repromed (Dulwich, Australia). Women in
good general health undergoing IVF treatment with a
frozen–thawed embryo transfer were eligible for inclusion
after diagnosis of likely immune-mediated implantation
failure, on the basis of no viable pregnancy despite transfer
of multiple good-quality embryos, together with evidence of
serum anti-nuclear antibodies (ANA) and/or anti-thyroid
antibodies (anti-thyroglobulin, anti-thyroid peroxidase)
(both from Australian Clinical Labs, Clayton, Australia), and/
or elevated endometrial NK cell density.84 Exclusion criteria
included use of any immune-modulating drugs
(corticosteroids, NSAIDs or methotrexate), positive serology
test for hepatitis B, hepatitis C, HIV or syphilis (Australian
Clinical Labs), suspected current infection
(temperature > 37.5°C on admission) or recent significant
physical trauma (injury or surgery). Women were recruited
over the 4-month period from June to September 2017. After
obtaining informed written consent, women were
administered 100 mL of 20% (v/v) Intralipid (Fresenius Kabi,
Sydney, AUS) dissolved in 900 mL of normal saline (Baxter,
Sydney, AUS), delivered by intravenous infusion over a 2- to
3-hour period, at approximately 4–5 days post-ovulation, just
prior to embryo transfer. Immediately prior to
commencement of Intralipid infusion, 20 mL of peripheral
blood (‘pre-Intralipid’) was collected for cytokine analysis,
complete blood leucocyte count and flow cytometric
analysis. A second 20-mL peripheral blood sample (‘post-
Intralipid’) was collected 7–10 days later, in the late-luteal
phase corresponding to the time of embryo implantation. All
women then received a second Intralipid infusion, according
to the same protocol as the first infusion. Other than
Intralipid infusion and peripheral blood collection, the
clinical protocol followed standard practice for modified
natural cycle frozen embryo transfer,85 including
administration of Oripro intravaginal micronised
progesterone (Orion Laboratories Pty Ltd, Balcatta, WA;
200 mg/day). No other drugs were administered. Clinical
outcome was classified initially as ‘embryo implantation’ or
‘no embryo implantation’ on the basis of plasma hCG
measured two weeks after embryo transfer. Then, in the
event of positive hCG, an ultrasound scan of the uterus was
performed in gestational week 7 and week 12. Pregnancy
outcome was recorded as early biochemical miscarriage
(EBM, before 12 weeks), ectopic pregnancy or live birth
(Table 1).
Plasma collection and isolation of
peripheral blood mononuclear cells
Peripheral blood was collected into EDTA-coated vacutainer
tubes, and centrifuged at 2000 9 g for 10 min at room
temperature. Plasma was aliquoted into 500 µL volumes and
stored at 80°C until later cytokine analysis by Luminex
microbead assay. The remaining blood was diluted in
PBS + 2% fetal calf serum (FCS) (StemcellTM Technologies,
Vancouver, CA) (room temperature) to a total volume twice
that of the original sample, then overlaid onto Lympholyte
(Cedarlane, Ontario, CA) and centrifugation at 600 9 g for
30 min at room temperature with no brake. The PBMC-
containing buffy coat was collected and washed twice with
Dulbecco’s modified PBS (DPBS) by centrifuging at 450 9 g
for 5 min. Cells were resuspended in complete media (RPMI
1640 containing 10% FBS and 1% penicillin/streptomycin
solution) and total viable cells counted using a Neubauer
haemocytometer. Following counting, cell concentration
was adjusted to 4–8 9 106 cells per mL in complete media
and diluted in an equal volume of freezing media
containing 20% DMSO (Sigma-Aldrich, NSW, AUS) and 80%
FBS (In Vitro Technologies, VIC, AUS), dropwise. Aliquots
(1 mL, 2–4 9 106) of PBMCs were then transferred into
cryovials and frozen to 80°C overnight, in a Mr FrostyTM
(Nalgene, New York, USA) controlled-rate freezing device.
The next day, PBMCs were transferred into vapour phase
liquid nitrogen storage until flow cytometry was performed.
Measurement of cytokines and chemokines
in plasma samples
Selected cytokines and chemokines including IL-2, IL-4, IL-
10, IL-12p70, IL-15 and IL-21 (Cat. No HTH17MAG-14K), and
CCL2, CCL3, CCL5, CXCL8, CXCL10, G-CSF, GM-CSF, GRO, IL-
1RA, IL-1A, IL-6, TNF and VEGF (Cat. No HCYTOMAG-60K)
were quantified in plasma samples using Milliplex MAP
Luminex microbead assays according to the manufacturer’s
instructions (Merck Millipore, Darmstadt, DE). Samples were
analysed without dilution in duplicate, and plates were
analysed on a Luminex MAGPIX instrument running
xPonent v4.2 software (Luminex Corp., Texas, USA).
Minimum detectable thresholds were 5.1 pg mL1 (IL-2),
9.0 pg mL1 (IL-4), 0.3 pg mL1 (IL-10), 1.1 pg mL1 (IL-
12p70), 2.7 pg mL1 (IL-15) and 2.0 pg mL1 (IL-21), as well
as 1.5 pg mL1 (CCL2), 1.9 pg mL1 (CCL3), 1.9 pg mL1
(CCL5), 1.9 pg mL1 (CXCL8), 2.1 pg mL1 (CXCL10),
1.8 pg mL1 (G-CSF), 3.1 pg mL1 (GM-CSF), 2.1 pg mL1
(CXCL1), 2.1 pg mL1 (IL-1RA), 3.3 pg mL1 (IL-1A),
2.0 pg mL1 (IL-6), 2.6 pg mL1 (TNF) and 3.7 pg mL1
(VEGF).
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Flow cytometric analysis
Cryopreserved PBMCs were thawed and counted with a
haemocytometer; then, 1 9 106 viable cells per sample were
rested overnight at 37°C in RPMI 1640 + 10% heat-
inactivated FBS. The following day, cells were stained with
viability dye (1/1000 dilution) in PBS with human FCcR block
(1/30 dilution) for 10 min. Anti-CCR7::BUV395 antibody was
added and incubated for a further 15 min before adding a
master mix of surface-staining antibodies prepared in
Brilliant Staining Buffer Plus (BD Biosciences)
(Supplementary table 1). Cells were incubated with
antibodies for 20 min, then rinsed and fixed and
permeabilised with fix/perm solution (BD Biosciences) for
30 min. After rinsing twice with permwash (BD Biosciences),
the cells were incubated with antibodies against
intracellular antigens for 40 min, then rinsed with
permwash and PBS and finally resuspended in PBS for
acquisition with a BD LSR Fortessa X20 flow cytometer. All
incubations were performed at room temperature.
Data and statistical analysis
All data were graphed and analysed with GraphPad Prism
for Windows (GraphPad Software, San Diego, California
USA, www.graphpad.com (version 9.0.0)). Flow cytometric
data were analysed with FlowJo software (BD Biosciences,
version 10.6.2). tSNE was performed on a downsample of
3500 pre-gated CD3+ T cells from each sample using default
parameters (perplexity = 30, theta = 0.5), according to
published protocols.86 Xshift clustering was performed with
the default Euclidean (k) value of 280, as described.87 Both
tSNE and Xshift were performed in FlowJo software where
the proportion of each cluster and MFI of each marker
were also calculated. Z-scores were manually calculated for
the MFIs as [(MFI(query) – minimum)/(maximum –
minimum)] to generate a heatmap using GraphPad Prism.
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